(From the Attorney General’s website)
“On August 20, 2021, the Minnesota Attorney General’s Office joined historic $26 billion multistate settlement agreements with pharmaceutical distributors McKesson, Cardinal Health, and AmerisourceBergen, and opioid manufacturer Johnson & Johnson. The settlements received final approval from the companies on February 25, 2022. The parties to these settlements are states and cities and counties.
On December 6, 2021 the Attorney General’s Office announced an agreement with Minnesota cities and counties on how funds from these settlements will be allocated: 75% to counties and cities that sign on, and 25% to the State, to be spent on opioid abatement.”
This webpage serves as a resource for Minnesotans – including staff from cities, counties and tribes – who are interested in updates and resources regarding the expenditure of funds from the opioid settlement.
Minnesota will be eligible to receive more than $296 million over 18 years. Up to $222 million of that will be paid directly to Minnesota cities and counties.
Counties and cities are required to report their calendar year settlement spending by March 31st of the proceeding year. Minnesota Department of Human Services (DHS) – in conjunction with Minnesota Management and Budget (MMB) – will publicly report spending by August 1st of every year.
To view current settlement expenditure reports, please click here to access MMB’s Opioid Epidemic Response Spending Dashboard. Select “Settlement Funds” in the Funding Source (Directed By) section of the dashboard, along with the year(s) you wish to view.
The Minnesota Department of Human Services (DHS) will collect, collate and publicly report this data.
This document was created by Dr. Weston Merrick, a senior manager at Minnesota Management and Budget (MMB). This document presents some helpful overview materials and resources outlining what is working in treating opioid use disorder (OUD) in Minnesota.
Evidence-Based Practices to Prevent, Treat and Advance Recovery of OUD (PDF)
If you have questions, please email BHD_Opioid@state.mn.us